Sławomir Mańdziuk

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

David Planchard, Niels Reinmuth, Jürgen R. Fischer et al. · Annals of Oncology · 2020 · 161 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Different Effects of Resveratrol on Dose-Related Doxorubicin-Induced Heart and Liver Toxicity

Jarosław Dudka, Renata Gieroba, Agnieszka Korga-Plewko et al. · Evidence-based Complementary and Alternative Medicine · 2012 · 77 citations · Full text

Medicine, Pharmacology, Toxicology +15